Pages that link to "Q36503712"

The following pages link to Psychotropic medication utilization in a child and adolescent mental health service (Q36503712):

Displaying 26 items.

• Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment (Q27028197) (← links)
• The behavioral organization, temporal characteristics, and diagnostic concomitants of rage outbursts in child psychiatric inpatients (Q33346910) (← links)
• Polypharmacy among children and adolescents with psychiatric disorders in a mental referral hospital in Botswana (Q33655284) (← links)
• Use of Psychotropic Medications among Youth in Treatment Foster Care (Q33699936) (← links)
• National Trends in Child and Adolescent Psychotropic Polypharmacy in Office-Based Practice, 1996-2007 (Q34187891) (← links)
• Antipsychotic polypharmacy in children and adolescents at discharge from psychiatric hospitalization (Q34194447) (← links)
• Clinical characteristics of depressed youths in child psychiatry. (Q35716240) (← links)
• Antidepressant prescribing in Irish children: secular trends and international comparison in the context of a safety warning (Q35771405) (← links)
• Long-term sustained benefits of clozapine treatment in refractory early onset schizophrenia: a retrospective study in Korean children and adolescents (Q37278334) (← links)
• Changing utilization of pro re nata ('as needed') sedation in a child and adolescent psychiatric inpatient unit (Q37417592) (← links)
• Aripiprazole in the treatment of early-onset schizophrenia spectrum disorder: A case series in Korean children and adolescents (Q37667320) (← links)
• Weight gain associated with taking psychotropic medication: an integrative review (Q37865068) (← links)
• Polypharmacy with antidepressants in children and adolescents (Q38063355) (← links)
• Combination pharmacotherapy for psychiatric disorders in children and adolescents: prevalence, efficacy, risks and research needs (Q38113748) (← links)
• Use of SSRIs among Danish children: a nationwide study (Q38184948) (← links)
• Atypical antipsychotics for disruptive behaviour disorders in children and youths (Q38632745) (← links)
• Off-label psychotropic prescribing for young persons in medium security (Q44195806) (← links)
• Psychotropic drug and polypharmacy use among adolescents and young adults: findings from the Finnish 1981 Nationwide Birth Cohort Study (Q44758533) (← links)
• Clinical Characteristics of Depressed Youths in Child Psychiatry (Q46451723) (← links)
• The use of antipsychotic medication in child and adolescent psychiatric treatment in Denmark. A cross-sectional survey (Q46482006) (← links)
• Factors associated with the use of intrusive measures at a tertiary care facility for children and youth with mental health and developmental disabilities. (Q47446826) (← links)
• Differential behavioural and neurochemical outcomes from chronic paroxetine treatment in adolescent and adult rats: a model of adverse antidepressant effects in human adolescents? (Q48909201) (← links)
• Use of restrictive interventions in a child and adolescent inpatient unit - predictors of use and effect on patient outcomes (Q50645766) (← links)
• Physical aggression during admission to a child and adolescent inpatient unit: predictors and impact on clinical outcomes. (Q51703136) (← links)
• Outpatient treatment of children and adolescents with antipsychotic drugs in Croatia (Q51815156) (← links)
• Psychotropic medication use in the child and adolescent psychiatry wards of a French hospital (Q51890586) (← links)